BioSante Pharmaceuticals to Present at Merriman Curhan Ford’s Investor Summit
Business Wire, Nov 10, 2009
LINCOLNSHIRE, Ill. — BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that
Phillip B. Donenberg, its CFO, will present an overview of the company
and its recently completed acquisition of Cell Genesys, as well as give
a LibiGel (testosterone gel) update at Merriman Curhan
Fords 6th Annual Investor Summit today, Tuesday November 10,
2009 at the Hotel Sofitel in New York City. Mr. Donenberg will present
at 12:40 pm local time.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health, menopause, contraception and male
hypogonadism. BioSantes lead products include LibiGel
(transdermal testosterone gel) in Phase III clinical development by
BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special
Protocol Assessment) for the treatment of female sexual dysfunction
(FSD), and Elestrin (estradiol gel) developed through FDA approval by
BioSante, indicated for the treatment of moderate-to-severe vasomotor
symptoms associated with menopause, currently marketed in the U.S
Nov 11, 2009
Comments
No comments yet, be the first to add one!